{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T12:40:45Z","timestamp":1771504845839,"version":"3.50.1"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005670","name":"Scientific Research Foundation","doi-asserted-by":"publisher","award":["20141685"],"award-info":[{"award-number":["20141685"]}],"id":[{"id":"10.13039\/501100005670","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Meta Gene"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.mgene.2016.07.002","type":"journal-article","created":{"date-parts":[[2016,7,5]],"date-time":"2016-07-05T22:36:39Z","timestamp":1467758199000},"page":"197-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"9","author":[{"given":"Jinhua","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunmei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.mgene.2016.07.002_bb0005","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.2217\/pgs.12.164","article-title":"Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans","volume":"13","author":"Bress","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"3","key":"10.1016\/j.mgene.2016.07.002_bb0010","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11239-006-9030-7","article-title":"Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study","volume":"22","author":"Carlquist","year":"2006","journal-title":"J. Thromb. Thrombolysis"},{"issue":"4","key":"10.1016\/j.mgene.2016.07.002_bb0015","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/clpt.2009.223","article-title":"Genetic and clinical predictors of warfarin dose requirements in African Americans","volume":"87","author":"Cavallari","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.mgene.2016.07.002_bb0020","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2125.2010.03698.x","article-title":"CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement","volume":"70","author":"Cen","year":"2010","journal-title":"British Journal Of Clinical Pharmacology"},{"issue":"23","key":"10.1016\/j.mgene.2016.07.002_bb0025","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1093\/hmg\/ddq389","article-title":"Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese","volume":"19","author":"Cha","year":"2010","journal-title":"Hum. Mol. Genet."},{"issue":"8","key":"10.1016\/j.mgene.2016.07.002_bb0030","doi-asserted-by":"crossref","first-page":"e105250","DOI":"10.1371\/journal.pone.0105250","article-title":"A pharmacogenetics-based warfarin maintenance dosing algorithm from northern chinese patients","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.mgene.2016.07.002_bb0035","first-page":"573","article-title":"Effects of VKORC1 and CYP2C9 gene polymorphisms on metabolism and pharmacodynamics of warfarin in elderly with artrial fibrillation","volume":"17","author":"Cheng","year":"2009","journal-title":"Chin. J. Clin. Neurosci."},{"issue":"10","key":"10.1016\/j.mgene.2016.07.002_bb0040","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00701-013-1747-4","article-title":"Association of VKORC1-1639G>A polymorphism with susceptibility to ossification of the posterior longitudinal ligament of the spine: a Korean study","volume":"155","author":"Chin","year":"2013","journal-title":"Acta Neurochir."},{"issue":"4","key":"10.1016\/j.mgene.2016.07.002_bb0045","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/jhg.2011.4","article-title":"Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients","volume":"56","author":"Choi","year":"2011","journal-title":"Eur. J. Hum. Genet."},{"issue":"Suppl. 3","key":"10.1016\/j.mgene.2016.07.002_bb0050","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1186\/1471-2164-14-S3-S11","article-title":"Pathway analysis of genome-wide data improves warfarin dose prediction","volume":"14","author":"Daneshjou","year":"2013","journal-title":"BMC Genomics"},{"key":"10.1016\/j.mgene.2016.07.002_bb0055","first-page":"1628","article-title":"Influence of CYP2C9 and VKORC1 pol ymorphisms on warfarin dose and anti-coagulative effect in chinese population","volume":"45","author":"Du","year":"2010","journal-title":"Chin. Pharm. J."},{"key":"10.1016\/j.mgene.2016.07.002_bb0060","author":"FDA"},{"key":"10.1016\/j.mgene.2016.07.002_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2014.05.028","article-title":"VKORC1 and CYP2C9 genotype distribution in Asian countries","author":"Gaikwad","year":"2014","journal-title":"Thromb. Res."},{"key":"10.1016\/j.mgene.2016.07.002_bb0070","first-page":"2053","article-title":". Effects of CYP2C9 and VKORC1 genetic polymorphisms on maintenance dosage and anticoagulation effect of warfarin in patients after undergoing mechanical heart valve prostheses replacement","volume":"21","author":"Gao","year":"2010","journal-title":"China Pharmacy"},{"issue":"12","key":"10.1016\/j.mgene.2016.07.002_bb0075","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00228-010-0863-9","article-title":"VKORC1-1639G\/A, CYP2C9, EPHX1691A\/G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China","volume":"66","author":"Gu","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.mgene.2016.07.002_bb0080","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1365-2125.1993.tb05703.x","article-title":"High clearance of (S)-warfarin in a warfarin-resistant subject","volume":"35","author":"Hallak","year":"1993","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.mgene.2016.07.002_bb0085","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/FPC.0b013e328326e0c7","article-title":"Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients","volume":"19","author":"Huang","year":"2009","journal-title":"Pharmacogenet. Genomics"},{"issue":"3","key":"10.1016\/j.mgene.2016.07.002_bb0090","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/FPC.0b013e328326e0c7","article-title":"Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: aprospective study in Chinese patients","volume":"19","author":"Huang","year":"2009","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.mgene.2016.07.002_bb0095","first-page":"35","article-title":"Study on the association between the maintenance dose of warfarin anticoagulation therapy and the genetic mutation of cytochrome P450 (CYP2C9)","volume":"16","author":"Huo","year":"2008","journal-title":"Chin. J. Prev. Contr. Chron. Non-commun. Dis."},{"key":"10.1016\/j.mgene.2016.07.002_bb0100","series-title":"Vitamin K Epoxide Reductase Complex 1 Gene Polymorphism and Warfarin Dose Requirement in Chinese Patients","first-page":"652","volume":"35","author":"Jiang","year":"2007"},{"issue":"8","key":"10.1016\/j.mgene.2016.07.002_bb0105","doi-asserted-by":"crossref","first-page":"e44064","DOI":"10.1371\/journal.pone.0044064","article-title":"Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis","volume":"7","author":"Jorgensen","year":"2012","journal-title":"Plos One"},{"key":"10.1016\/j.mgene.2016.07.002_bb0110","series-title":"The Cochrane Handbook: v5.1.0; 2011. Part 2:8.5","author":"Julian","year":"2011"},{"issue":"11","key":"10.1016\/j.mgene.2016.07.002_bb0115","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1001\/jama.282.11.1054","article-title":"The hazards of scoring the quality of clinical trials for meta-analysis","volume":"282","author":"J\u00fcni","year":"1999","journal-title":"J. Am. Med. Assoc."},{"issue":"8","key":"10.1016\/j.mgene.2016.07.002_bb0120","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa0809329","article-title":"Estimation of the warfarin dose with clinical and pharmacogenetic data","volume":"360","author":"Klein","year":"2009","journal-title":"The New England Journal Of Medicine"},{"issue":"9","key":"10.1016\/j.mgene.2016.07.002_bb0125","first-page":"563","article-title":"Frequencies of polymorphisms in CYP2C9 and VKORC1 genes influencing warfarin metabolism in Slovak population: implication for clinical practice","volume":"115","author":"Krajciova","year":"2014","journal-title":"Bratisl. Lek. Listy"},{"key":"10.1016\/j.mgene.2016.07.002_bb0130","first-page":"739751","article-title":"Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction","author":"Kringen","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"issue":"1","key":"10.1016\/j.mgene.2016.07.002_bb0135","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00228-013-1581-x","article-title":"Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population","volume":"70","author":"Krishna Kumar","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.mgene.2016.07.002_bb0140","doi-asserted-by":"crossref","first-page":"301","DOI":"10.4103\/0971-6866.120817","article-title":"Inter and intra ethnic variation of vitamin K epoxide reductase complex and cytochrome P450 4F2 genetic polymorphisms and their prevalence in South Indian population","volume":"19","author":"Kumar","year":"2013","journal-title":"Indian Journal Of Human Genetics"},{"issue":"3","key":"10.1016\/j.mgene.2016.07.002_bb0145","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.clpt.2005.11.006","article-title":"Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population","volume":"79","author":"Lee","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.mgene.2016.07.002_bb0150","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.2217\/pgs.09.106","article-title":"Genetic determinants of warfarin dosing in the Han-Chinese population","volume":"10","author":"Lee","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.mgene.2016.07.002_bb0155","first-page":"670","article-title":"CYP2C9 and VKORC1 polymorphisms are associated with Warfarin Anticoagulation-Dose Requirements","volume":"38","author":"Li","year":"2010","journal-title":"Tianjin Med. J."},{"key":"10.1016\/j.mgene.2016.07.002_bb0160","first-page":"1749","article-title":"Correlation between single nucleotide polymorphisms in CYP4F2 and warfarin dosing in Chinese valve replacement patients","author":"Li","year":"2012","journal-title":"J. Cardiothorac. Surg."},{"issue":"1","key":"10.1016\/j.mgene.2016.07.002_bb0165","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.thromres.2011.11.043","article-title":"Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and meta-analysis","volume":"130","author":"Liang","year":"2012","journal-title":"Thromb. Res."},{"issue":"1","key":"10.1016\/j.mgene.2016.07.002_bb0170","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11239-012-0725-7","article-title":"Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients","volume":"34","author":"Liang","year":"2012","journal-title":"Journal Of Thrombosis And Thrombolysis"},{"issue":"12","key":"10.1016\/j.mgene.2016.07.002_bb0175","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1089\/gtmb.2013.0303","article-title":"Association of genetic polymorphisms with warfarin dose requirements in Chinese patients","volume":"17","author":"Liang","year":"2013","journal-title":"Genet. Test. Mol. Biomarkers"},{"issue":"2","key":"10.1016\/j.mgene.2016.07.002_bb0180","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/sj.clpt.6100290","article-title":"Influence of CYP2C9 and VKORC1 1173C\/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin","volume":"83","author":"Limdi","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.mgene.2016.07.002_bb0185","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00228-008-0584-5","article-title":"Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis","volume":"65","author":"Lindh","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.mgene.2016.07.002_bb0190","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00228-008-0584-5","article-title":"Influence of CYP2C9 genotype on warfarin dose requirements\u2014a systematic review and meta-analysis","volume":"65","author":"Lindh","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.mgene.2016.07.002_bb0195","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/oxfordjournals.aje.a000179","article-title":"Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations","volume":"156","author":"Little","year":"2002","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.mgene.2016.07.002_bb0200","first-page":"240","article-title":"Effects of CYP2C9 gene polymorphisms and age in Chinese Han patients on warfarin dose","volume":"12","author":"Liu","year":"2010","journal-title":"Adverse Drug Reactions Journal"},{"key":"10.1016\/j.mgene.2016.07.002_bb0205","first-page":"202","article-title":"Influence of CYP2C9 and VKORC1 genetic polymorphisms on maintenance warfarin dose in Chinese pulmonary embolism ptients","volume":"9","author":"Lou","year":"2012","journal-title":"Chinese Journal of Pharmacovigilance"},{"issue":"7","key":"10.1016\/j.mgene.2016.07.002_bb0210","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40262-013-0054-9","article-title":"Prediction of warfarin maintenance dose in Han Chinese patients using a mechanistic model based on genetic and non-genetic factors","volume":"52","author":"Lu","year":"2013","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.mgene.2016.07.002_bb0215","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s12185-012-1205-8","article-title":"Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin","volume":"96","author":"Ma","year":"2012","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.mgene.2016.07.002_bb0220","first-page":"185","article-title":"Effect of multiplesigle-nucleotide variants in VKORC1 gene on the maintenance doses of warfarin","volume":"37","author":"Meng","year":"2011","journal-title":"Jiangsu Med. J."},{"issue":"12","key":"10.1016\/j.mgene.2016.07.002_bb0225","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s00228-007-0381-6","article-title":"Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients","volume":"63","author":"Miao","year":"2007","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.mgene.2016.07.002_bb0230","doi-asserted-by":"crossref","unstructured":"M-S Wen.pdf. doi: 10.1038\/sj.clpt.6100453[published Online First: Epub Date].","DOI":"10.1038\/sj.clpt.6100453"},{"issue":"3","key":"10.1016\/j.mgene.2016.07.002_bb0235","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10038-005-0354-5","article-title":"Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients","volume":"51","author":"Mushiroda","year":"2006","journal-title":"Eur. J. Hum. Genet."},{"issue":"12","key":"10.1016\/j.mgene.2016.07.002_bb0240","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3949\/ccjm.76a.09062","article-title":"An algorithm for managing warfarin resistance","volume":"76","author":"Osinbowale","year":"2009","journal-title":"Cleve. Clin. J. Med."},{"key":"10.1016\/j.mgene.2016.07.002_bb0245","first-page":"1533","article-title":"Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose","author":"Rieder","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.mgene.2016.07.002_bb0250","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/01.GIM.0000153664.65759.CF","article-title":"CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a systematic review and meta-analysis","volume":"7","author":"Sanderson","year":"2005","journal-title":"Genetics In Medicine"},{"issue":"2","key":"10.1016\/j.mgene.2016.07.002_bb0255","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ajhg.2007.10.002","article-title":"Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations","volume":"82","author":"Scott","year":"2008","journal-title":"American Journal Of Human Genetics"},{"issue":"10","key":"10.1016\/j.mgene.2016.07.002_bb0260","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00228-013-1544-2","article-title":"Cytochrome P450 oxidoreductase genetic polymorphisms A503V and rs2868177 do not significantly affect warfarin stable dosage in Han-Chinese patients with mechanical heart valve replacement","volume":"69","author":"Tan","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.mgene.2016.07.002_bb0265","first-page":"44","article-title":"Effects of VKORC1 gene polymorphisms on warfarin doses in Han Chinese patients with venous thromboembolism","volume":"7","author":"Tang","year":"2009","journal-title":"Clin. Med. J."},{"key":"10.1016\/j.mgene.2016.07.002_bb0270","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/01.fpc.0000174789.77614.68","article-title":"Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population","volume":"15","author":"Veenstra","year":"2005","journal-title":"Pharmacogenet. Genomics"},{"issue":"3","key":"10.1016\/j.mgene.2016.07.002_bb0275","article-title":"A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose","volume":"5","author":"Visscher","year":"2009","journal-title":"PLoS Genet."},{"issue":"4","key":"10.1016\/j.mgene.2016.07.002_bb0280","first-page":"262","article-title":"Common VKORC1 and GGCX polymorphisms associated with warfarin dose","volume":"5","author":"Wadelius","year":"2005","journal-title":"Pharm. J."},{"issue":"4","key":"10.1016\/j.mgene.2016.07.002_bb0285","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2008-04-149070","article-title":"The largest prospective warfarin-treated cohort supports genetic forecasting","volume":"113","author":"Wadelius","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.mgene.2016.07.002_bb0290","first-page":"1360","article-title":"Effects of CYP2C9*3 and VKORC1 gene polymorphisms on warfarinin prevention of deep venous thrombosis of lower limbs after orthopedic surgery","volume":"33","author":"Wang","year":"2013","journal-title":"Journal of Shanghai Jiaotong University (Medical science)"},{"key":"10.1016\/j.mgene.2016.07.002_bb0295","first-page":"3091","article-title":"Impact of CYP4F2 genetic polymorphisms on warfarin maintenance dose","volume":"32","author":"Wang","year":"2011","journal-title":"Guangdong Medical Journal"},{"issue":"6","key":"10.1016\/j.mgene.2016.07.002_bb0300","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1160\/TH11-12-0848","article-title":"A new algorithm to predict warfarin dose from polymorphisms of CYP4F2, CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation","volume":"107","author":"Wei","year":"2012","journal-title":"Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.mgene.2016.07.002_bb0305","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.thromres.2014.06.022","article-title":"Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms","volume":"134","author":"Wypasek","year":"2014","journal-title":"Thromb. Res."},{"issue":"1","key":"10.1016\/j.mgene.2016.07.002_bb0310","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1146\/annurev.pharmtox.41.1.815","article-title":"Molecular basis of ethnic differences in drug disposition and response","volume":"41","author":"Xie","year":"2001","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.mgene.2016.07.002_bb0315","series-title":"Master's Thesis of Kunming Medical University","article-title":"CYP2C9 gene polymorphism influence patients with atrial fibrillations warfarin doses","author":"Yang","year":"2012"},{"issue":"4","key":"10.1016\/j.mgene.2016.07.002_bb0320","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.thromres.2009.10.017","article-title":"Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement-a systematic review and meta analysis","volume":"125","author":"Yang","year":"2010","journal-title":"Thromb. Res."},{"issue":"01","key":"10.1016\/j.mgene.2016.07.002_bb0325","doi-asserted-by":"crossref","first-page":"23","DOI":"10.5414\/CPP49023","article-title":"Contribution of 1173C>T polymorphism in the VKORC1 gene to warfarin dose requirements in Han Chinese patients receiving anticoagulation","volume":"49","author":"Yang","year":"2011","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.mgene.2016.07.002_bb0330","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/0300060513499094","article-title":"Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients","volume":"42","author":"Ye","year":"2014","journal-title":"J. Int. Med. Res."},{"issue":"2","key":"10.1016\/j.mgene.2016.07.002_bb0335","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.thromres.2008.11.011","article-title":"Effect of VKORC1-1639 G>A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients","volume":"124","author":"Yoshizawa","year":"2009","journal-title":"Thromb. Res."},{"issue":"13","key":"10.1016\/j.mgene.2016.07.002_bb0340","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/hmg\/ddi180","article-title":"A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity","volume":"14","author":"Yuan","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mgene.2016.07.002_bb0345","first-page":"1193","article-title":"Relationship between warfarin maintainance dose after mechanical heart valve prostheses implantation and polymorphisms of CYP2C9 on low anticoagulant level","volume":"17","author":"Zhang","year":"2007","journal-title":"Chin. J. Health Lab. Technol."},{"key":"10.1016\/j.mgene.2016.07.002_bb0350","first-page":"396","article-title":"Influence of VKORC1\u20131639G\/A and CYP2C9 1061A\/C polymorphisms on warfarin dose","volume":"4","author":"Zhang","year":"2007","journal-title":"J. Med. Mol. Biol."},{"issue":"3","key":"10.1016\/j.mgene.2016.07.002_bb0355","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2217\/pgs.11.147","article-title":"Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism","volume":"13","author":"Zhang","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.mgene.2016.07.002_bb0360","first-page":"338","article-title":"Effect of CYP4F2 genetic polymorphisms on warfarin maintenance dose","volume":"18","author":"Zhang","year":"2012","journal-title":"Pharm. Clin. Res."},{"key":"10.1016\/j.mgene.2016.07.002_bb0365","first-page":"862","article-title":"Effect of CYP2C9 genetic polymorphisms on warfarin dosage and anticoagulation","volume":"43","author":"Zheng","year":"2008","journal-title":"Chin. J. Pharm."},{"key":"10.1016\/j.mgene.2016.07.002_bb0370","first-page":"13","article-title":"Influence of warfarin related genes and non- genetic factors on administrative dose in Shanghai area","volume":"35","author":"Zhuang","year":"2014","journal-title":"Chin. J. Hemotal."}],"container-title":["Meta Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214540016300251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214540016300251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T13:17:19Z","timestamp":1600867039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214540016300251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":74,"alternative-id":["S2214540016300251"],"URL":"https:\/\/doi.org\/10.1016\/j.mgene.2016.07.002","relation":{},"ISSN":["2214-5400"],"issn-type":[{"value":"2214-5400","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Meta Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mgene.2016.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}